Published in Clin Cancer Res on May 01, 1998
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res (2000) 3.41
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer (2002) 2.53
Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE). Biochem J (2000) 2.29
A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol (2007) 2.07
High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther (2007) 1.88
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer (2002) 1.49
Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases. Gut (2014) 1.48
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther (2007) 1.37
Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev (2004) 1.27
Coordinate regulation of IL-1beta and MMP-13 in rat tendons following subrupture fatigue damage. Clin Orthop Relat Res (2008) 1.16
Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis (2001) 1.13
Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am J Pathol (2010) 1.02
Clinical trial design for target specific anticancer agents. Invest New Drugs (2003) 0.98
Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br J Cancer (1999) 0.93
Matrix metalloproteinase inhibitors: applications in oncology. Invest New Drugs (1999) 0.92
Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer (1999) 0.92
Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel) (2014) 0.92
Matrix metalloproteinases in gastrointestinal cancer. Gut (1998) 0.91
Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model. Clin Exp Metastasis (2002) 0.88
EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma. Future Oncol (2009) 0.88
Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol (2014) 0.87
Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res Ther (2002) 0.83
Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening. Int J Mol Sci (2013) 0.82
A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma. HPB (Oxford) (2005) 0.81
Development of target-based antineoplastic agents. Invest New Drugs (2000) 0.81
Reduction of experimental laser-induced choroidal neovascularization by orally administered BPHA, a selective metalloproteinase inhibitor. Graefes Arch Clin Exp Ophthalmol (2003) 0.80
Feasibility of measuring prostate perfusion with arterial spin labeling. NMR Biomed (2012) 0.78
A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br J Cancer (2004) 0.77
Pharmacokinetic-pharmacodynamic guided trial design in oncology. Invest New Drugs (2003) 0.77
Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy. Front Cell Dev Biol (2014) 0.76
Missing value estimation methods for DNA microarrays. Bioinformatics (2001) 20.84
Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care (1988) 9.27
Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet (1998) 7.70
Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol (1999) 6.98
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challenges. Am J Bioeth (2009) 6.13
Human infection with Ehrlichia canis, a leukocytic rickettsia. N Engl J Med (1987) 6.06
Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature (1984) 5.53
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biol (2000) 5.29
Cell communication, calcium ion, and cyclic adenosine monophosphate. Science (1970) 5.25
Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol). Lancet (1974) 4.95
Colorectal cancer. Lancet (1999) 4.72
Quality of life measures in health care. I: Applications and issues in assessment. BMJ (1992) 4.53
Human immunodeficiency virus integration in a cell-free system. J Virol (1990) 4.48
Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology (2001) 4.44
Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet (1997) 4.43
Beyond the confidence interval. Am J Public Health (1987) 4.27
Waiting times for cancer patients in England after general practitioners' referrals: retrospective national survey. BMJ (2000) 4.13
Genetic control of natural variation in Arabidopsis glucosinolate accumulation. Plant Physiol (2001) 4.07
Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science (1992) 3.93
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
Relationships between calcium and cyclic nucleotides in cell activation. Physiol Rev (1977) 3.45
Calcium messenger system: an integrated view. Physiol Rev (1984) 3.34
Community clinics for leg ulcers and impact on healing. BMJ (1992) 3.28
A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab (2001) 3.16
A pooled analysis of magnetic fields, wire codes, and childhood leukemia. Childhood Leukemia-EMF Study Group. Epidemiology (2000) 3.09
Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med (1990) 3.04
Vaginal repair with mesh versus colporrhaphy for prolapse: a randomised controlled trial. BJOG (2009) 3.04
Mutations in familial Creutzfeldt-Jakob disease and Gerstmann-Sträussler-Scheinker's syndrome. Exp Neurol (1989) 3.00
Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev (1999) 2.96
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Invariants and noninvariants in the concept of interdependent effects. Scand J Work Environ Health (1988) 2.82
Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci U S A (1999) 2.76
TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut (2011) 2.75
Course of tic severity in Tourette syndrome: the first two decades. Pediatrics (1998) 2.75
Creutzfeldt-Jakob disease and bovine spongiform encephalopathy: any connection? BMJ (1995) 2.74
Bias inherent in retrospective waiting-time studies: experience from a vascular surgery waiting list. CMAJ (2000) 2.74
Cyclic adenosine 3':5'-monophosphate-stimulated phosphorylation of isolated neurotubule subunits. Proc Natl Acad Sci U S A (1970) 2.56
Transmissible familial Creutzfeldt-Jakob disease associated with five, seven, and eight extra octapeptide coding repeats in the PRNP gene. Proc Natl Acad Sci U S A (1991) 2.55
A mechanism for the reactions of calcium with mitochondria. Proc Natl Acad Sci U S A (1965) 2.54
DNA sequences of two yeast promoter-up mutants. Nature (1983) 2.50
The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol (2013) 2.48
Further evidence for small-bodied hominins from the Late Pleistocene of Flores, Indonesia. Nature (2005) 2.47
Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci U S A (2000) 2.46
Cyclic adenosine monophosphate, CA++, and membranes. Proc Natl Acad Sci U S A (1968) 2.46
The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology (1987) 2.46
Science and policy making. Am J Public Health (1985) 2.45
Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation (2001) 2.43
An extremely luminous X-ray outburst at the birth of a supernova. Nature (2008) 2.41
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol (2001) 2.39
Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N Engl J Med (1982) 2.34
Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man. Exp Brain Res (1993) 2.30
Quality of life measures in health care. II: Design, analysis, and interpretation. BMJ (1992) 2.28
Presenting statistical uncertainty in trends and dose-response relations. Am J Epidemiol (1999) 2.27
New clinical sign for orthostatic tremor. Lancet (1995) 2.25
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22
Genome microarray analysis of transcriptional activation in multidrug resistance yeast mutants. FEBS Lett (2000) 2.22
Cognitive dysfunction 1-2 years after non-cardiac surgery in the elderly. ISPOCD group. International Study of Post-Operative Cognitive Dysfunction. Acta Anaesthesiol Scand (2000) 2.21
Differential expression of TGF beta 1, beta 2 and beta 3 genes during mouse embryogenesis. Development (1991) 2.21
Reassessing the role of epidemiology in public health. Am J Public Health (1999) 2.20
Gastric cancer detection in gastric ulcer disease. Gut (1980) 2.20
A strengthening programme for weak associations. Int J Epidemiol (1988) 2.19
Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man. J Pharmacol Exp Ther (1965) 2.16
Bovine spongiform encephalopathy [corrected] Creutzfeldt-Jakob disease. BMJ (1996) 2.15
Precautions in medical care of, and in handling materials from, patients with transmissible virus dementia (Creutzfeldt-Jakob disease). N Engl J Med (1977) 2.10
Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10
Characterization of transposable element-associated mutations that alter yeast alcohol dehydrogenase II expression. Mol Cell Biol (1983) 2.09
A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE). Health Technol Assess (2009) 2.09
Dose-effect relationships of trauma to symptoms of depression and post-traumatic stress disorder among Cambodian survivors of mass violence. Br J Psychiatry (1998) 2.08
Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol (1986) 2.06
Diagnosis of Creutzfeldt-Jakob disease by Western blot identification of marker protein in human brain tissue. N Engl J Med (1986) 2.06
Fenoterol and fatal asthma. Lancet (1990) 2.05
Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol (2001) 2.03
Experimentally induced hypoglycaemia. Lancet (1996) 2.02
Supervised harvesting of expression trees. Genome Biol (2001) 2.02
The future of general medicine. J R Coll Physicians Lond (1998) 2.02
Comparing health inequality in men and women: prospective study of mortality 1986-96. BMJ (2000) 2.00
Clinical and electrophysiological differences between patients with arrhythmogenic right ventricular dysplasia and right ventricular outflow tract tachycardia. Eur Heart J (2003) 1.99
Estimating cancer risk in relation to tritium exposure from routine operation of a nuclear-generating station in Pickering, Ontario. Chronic Dis Inj Can (2013) 1.97
Hormonal control of the renal conversion of 25-hydroxycholecalciferol to 1,25-dihydroxycholecalciferol. J Clin Invest (1972) 1.93
A "SMART" design for building individualized treatment sequences. Annu Rev Clin Psychol (2011) 1.89
Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol (1998) 1.89
Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol (1986) 1.87
Tissue handling in suspected Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases) Brain Pathol (1995) 1.86
Transformation of biphasic calcium phosphate ceramics in vivo: ultrastructural and physicochemical characterization. J Biomed Mater Res (1989) 1.85
Chiropractic care of children with nocturnal enuresis: a prospective outcome study. J Manipulative Physiol Ther (1991) 1.85
Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Sträussler-Scheinker disease. Proc Natl Acad Sci U S A (1998) 1.85
Assessment of aggression in psychiatric admissions: semistructured interview and case note survey. BMJ (2000) 1.85
Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol (1999) 1.85
Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism. Proc Natl Acad Sci U S A (1994) 1.85
Collaborative annotation of genes and proteins between UniProtKB/Swiss-Prot and dictyBase. Database (Oxford) (2009) 1.85
Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med (2006) 1.84
Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J Immunol (1984) 1.84
A requirement for ARF6 in Fcgamma receptor-mediated phagocytosis in macrophages. J Biol Chem (1998) 1.82
Typing prion isoforms. Nature (1997) 1.82
Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr (1995) 1.81
Risk-adjusted analysis of surgeon performance: a 1-year study. Br J Surg (1995) 1.81
Protein kinase C in the regulation of smooth muscle contraction. FASEB J (1987) 1.81
Expression of the gene defect in X-linked agammaglobulinemia. N Engl J Med (1986) 1.80
Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A (1998) 1.80